Skip to main content

Table 1 Demographic/baseline characteristics: by presence/absence of pain at baseline (as rated by Likert pain scale)

From: Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hocanalysis of the RECOVER study

  ‘No’ pain (n = 80) (pain score 0) ‘Any’ pain (n = 187)
(pain score ≥1)
‘Mild’ pain (n = 87) ‘Moderate-to-severe’ pain (n = 100)
   (pain score 1–3) (pain score ≥4)
Age, years 66.4 ± 9.3 (37–86) 63.8 ± 9.8 (37–85); (p = 0.048)
   63.1 ± 10.4 (37–85); (p = 0.032) 64.5 ± 9.3 (40–83); (p = 0.175)
Female 23 (29) 69 (37); (p = 0.199)
   23 (26); (p = 0.738) 46 (46); (p = 0.018)
Time since diagnosis, years 4.7 ± 4.4 (0.0–22.9) 4.9 ± 4.4 (0.0–25.6); (p = 0.820)
   4.5 ± 3.8 (0.0–17.2); (p = 0.765) 5.1 ± 4.9 (0.0–25.6); (p = 0.555)
Taking levodopa (advanced PD) 62 (78) 156 (83); (p = 0.252)
   70 (80); (p = 0.639) 86 (86); (p = 0.138)
UPDRS III total score 28.3 ± 11.1 31.3 ± 13.5; (p = 0.075)
   29.2 ± 11.9; (p = 0.621) 33.2 ± 14.5; (p = 0.013)
PDSS-2 total score 16.0 ± 7.8 21.2 ± 9.8; (p <0.0001)
   18.6 ± 9.2; (p = 0.048) 23.5 ± 9.8; (p <0.0001)
  1. Data are mean ± SD (range) or number of patients (%). Data are presented for the FAS.
  2. P values (t-test for continuous data, Chi-square test for categorical data; exploratory analyses) are reported for patients with ‘Any’ pain, ‘Mild’ pain, and ‘Moderate-to-severe’ pain vs patients with ‘No’ pain at baseline (assessed by the Likert pain scale).
  3. FAS: full analysis set; PD: Parkinson’s disease; PDSS-2: Parkinson’s Disease Sleep Scale; SD: standard deviation; UPDRS III: Unified Parkinson’s Disease Rating Scale.